The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease
S Janelidze, D Bali, NJ Ashton, NR Barthélemy… - Brain, 2023 - academic.oup.com
Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …
Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab
M Shi, F Chu, F Zhu, J Zhu - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ …
In Alzheimer's disease (AD), tau phosphorylation in the brain and its subsequent release
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease …
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
SE Schindler, JG Bollinger, V Ovod, KG Mawuenyega… - Neurology, 2019 - AAN Enterprises
Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …
Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease
Importance There is an urgent need for inexpensive and minimally invasive blood
biomarkers for Alzheimer disease (AD) that could be used to detect early disease changes …
biomarkers for Alzheimer disease (AD) that could be used to detect early disease changes …
Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques
Y Li, SE Schindler, JG Bollinger, V Ovod… - Neurology, 2022 - AAN Enterprises
Background and Objectives To determine the diagnostic accuracy of a plasma Aβ42/Aβ40
assay in classifying amyloid PET status across global research studies using samples …
assay in classifying amyloid PET status across global research studies using samples …
Biomarkers for Alzheimer's disease: current status and prospects for the future
K Blennow, H Zetterberg - Journal of internal medicine, 2018 - Wiley Online Library
Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …